Latest news and upcoming events
Mirum Pharmaceuticals and Vivet Therapeutics enter into exclusive worldwide option and license agreement for Vivet’s gene therapy programs targeting PFIC
Vivet to lead pre-clinical development of its two gene therapy programs for PFIC3 and PFIC2.
Minoryx Phase 2/3 ‘ADVANCE’ study results to be presented at the 2021 American Neurological Association (AAN) Annual Meeting
Overall results support the positive effects of leriglitazone on reducing the progression of cerebral lesions and myelopathy symptoms.
LAVA Therapeutics Announces Pricing of Initial Public Offering
Gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by LAVA, are expected to be $100.5 million.
Aura Biosciences Announces Oversubscribed $80 Million Financing
Ysios Capital joins Aura Biosciences 80MUSD financing
AELIX Therapeutics presents positive results from randomized placebo-controlled phase I/IIa therapeutic HIV vaccine clinical trial
Results support development of combination strategies based on HTI vaccine to control HIV – without the need for ongoing antiretroviral medication
ONA Therapeutics appoints Mark Throsby to its Board of Directors
Dr. Mark Throsby is a biopharmaceutical executive with extensive research experience and a track record of innovation and execution.
New Data Supports High Reperfusion Rate for Anaconda Biomed’s Mechanical Thrombectomy System
In Vitro Study, Showing Suction Force Correlates with Reperfusion in Hard Clots, Published in Journal of NeuroInterventional Surgery
MedLumics closes upsized EUR 18M (21.7M USD) financing round and appoints new Chairman
Financing to advance optically-guided real-time ablation catheter technology for the treatment of Atrial Fibrillation.
Sanifit Granted Orphan Drug Designation by the FDA for SNF472 for the Treatment of Peripheral Arterial Disease in Patients with End-stage Kidney Disease
Sanifit today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its lead compound SNF472 for the treatment of peripheral arterial disease (PAD) in patients with end-stage kidney disease (ESKD).
CorWave Joins the French Tech 120 Index, a Community That Brings Together the Top French Tech Scale-up Companies
The company develops breakthrough cardiac pumps with the aim of improving the lives of advanced heart failure patients
Subscribe to our weekly newsletter for the latest
updates on life sciences investments.